

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://www.fdi-lab.org) on Apr 1, 2025

A-375

RRID:CVCL_0132

Type: Cell Line

Proper Citation

(RRID:CVCL_0132)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0132

Proper Citation: (RRID:CVCL_0132)

Sex: Female

Defining Citation: [PMID:77569](#), [PMID:265522](#), [PMID:327080](#), [PMID:375235](#), [PMID:833871](#), [PMID:1832891](#), [PMID:3518877](#), [PMID:4357758](#), [PMID:6220172](#), [PMID:6500159](#), [PMID:6584666](#), [PMID:6954533](#), [PMID:9670966](#), [PMID:9973934](#), [PMID:10497214](#), [PMID:12068308](#), [PMID:14871852](#), [PMID:15009714](#), [PMID:15467732](#), [PMID:17308088](#), [PMID:18172304](#), [PMID:19727395](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21343389](#), [PMID:21424129](#), [PMID:21673604](#), [PMID:21857157](#), [PMID:22178978](#), [PMID:22282976](#), [PMID:22460905](#), [PMID:23039341](#), [PMID:24581590](#), [PMID:25056119](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26405815](#), [PMID:26589293](#), [PMID:26673621](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29275043](#), [PMID:29492214](#), [PMID:29605720](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35128241](#), [PMID:35839778](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Secretome proteome analysis., Omics: Proteome analysis by 2D-DE/MS., Omics: Protein expression by reverse-phase protein arrays., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep phosphoproteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Omics: Array-based CGH., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: A-375

Synonyms: A 375, A375, A375-MEL, A375-mel, A375mel, 375

Cross References: BTO:BTO_0002806, CLO:CLO_0001544, CLO:CLO_0001581, CLO:CLO_0001582, EFO:EFO_0002103, MCCL:MCC:0000024, CLDB:cl198, CLDB:cl199, Abcam:ab275461, AddexBio:C0020004/4992, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1619, ATCC:CRL-7904, BCRC:60039, BCRJ:0278, BioGRID_ORCS_Cell_line:44, BioSample:SAMN03472142, BioSample:SAMN05292441, BioSample:SAMN07709998, BioSample:SAMN07709999, BioSample:SAMN07710000, BioSample:SAMN07710001, BioSample:SAMN07710002, BioSample:SAMN07710003, BioSample:SAMN07710004, BioSample:SAMN10988347, cancercellines:CVCL_0132, CCRID:1101HUM-PUMC000126, CCRID:1101HUM-PUMC000327, CCRID:3101HUMSCSP533, CCRID:3101HUMTCHu155, CCRID:4201HUM-CCTCC00285, CCTCC:GDC0285, CCTCC:GDC0314, Cell_Model_Passport:SIDM00795, CGH-DB:9313-4, ChEMBL-Cells:ChEMBL3308077, ChEMBL-Targets:ChEMBL613859, CLS:300110, Cosmic:686480, Cosmic:687431, Cosmic:706114, Cosmic:876698, Cosmic:888861, Cosmic:897482, Cosmic:897735, Cosmic:905226, Cosmic:906793, Cosmic:928688, Cosmic:933003, Cosmic:1006556, Cosmic:1022280, Cosmic:1054855, Cosmic:1132587, Cosmic:1155278, Cosmic:1211162, Cosmic:1303032, Cosmic:1458961, Cosmic:1459655, Cosmic:1477406, Cosmic:1481413, Cosmic:1507620, Cosmic:1537486, Cosmic:1555009, Cosmic:1669118, Cosmic:1812178, Cosmic:1888914, Cosmic:1890486, Cosmic:1989294, Cosmic:1995332, Cosmic:2036699, Cosmic:2230112, Cosmic:2233660, Cosmic:2479252, Cosmic:2791113, Cosmic-CLP:906793, DepMap:ACH-000219, ECACC:88113005, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, ENCODE:ENCBS606AAA, ENCODE:ENCBS607AAA, GDSC:906793, GEO:GSM206443, GEO:GSM218051, GEO:GSM274681, GEO:GSM276771, GEO:GSM555121, GEO:GSM555173, GEO:GSM827158, GEO:GSM886854, GEO:GSM887919, GEO:GSM952580, GEO:GSM1092559, GEO:GSM1138787, GEO:GSM1177892, GEO:GSM1177893, GEO:GSM1374382, GEO:GSM1669582, GEO:GSM1671962, GEO:GSM1671967, GEO:GSM1671977, GEO:GSM1671981, GEO:GSM1671982, GEO:GSM1671987, GEO:GSM1671990, GEO:GSM1672001, GEO:GSM1672004, GEO:GSM1672007, GEO:GSM1672011, GEO:GSM1672017, GEO:GSM1672024, GEO:GSM1672027, GEO:GSM1672030, GEO:GSM1672039, GEO:GSM1672051, GEO:GSM1672062, GEO:GSM1672067, GEO:GSM1672078, GEO:GSM1672097, GEO:GSM1672102, GEO:GSM1672119, GEO:GSM1672135, GEO:GSM3039510, GEO:GSM3039516, GEO:GSM3039517, GEO:GSM3039518, IARC_TP53:21163, IBRC:C10141, IGRhCellID:A375, IZSLER:BS TCL 88, KCB:KCB 99003YJ, LiGeA:CCL_226, LINCS_HMS:50060, LINCS_LDP:LCL-1235, Lonza:970, NCBI_Iran:C136, PharmacDB:A375_42_2019, PRIDE:PXD001485, PRIDE:PXD004343, PRIDE:PXD005912, PRIDE:PXD007265, PRIDE:PXD021877, PRIDE:PXD022992, PRIDE:PXD025255, PRIDE:PXD025881, PRIDE:PXD026952, PRIDE:PXD027886, PRIDE:PXD028863, PRIDE:PXD030304, Progenetix:CVCL_0132,

PubChem_Cell_line:CVCL_0132, Ubigen:YC-C036, Wikidata:Q54605986

ID: CVCL_0132

Record Creation Time: 20250131T193537+0000

Record Last Update: 20250131T193616+0000

Ratings and Alerts

No rating or validation information has been found for A-375.

Warning: Discontinued: ATCC; CRL-7904

Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Secretome proteome analysis., Omics: Proteome analysis by 2D-DE/MS., Omics: Protein expression by reverse-phase protein arrays., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep phosphoproteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Omics: Array-based CGH., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3383 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Ren Z, et al. (2025) A peptide encoded by LINC00944 suppresses the growth of melanoma cells by diminishing EP400-MYC interaction. *Biochemical pharmacology*, 231, 116652.

Weingarten-Gabbay S, et al. (2024) The HLA-II immunopeptidome of SARS-CoV-2. *Cell reports*, 43(1), 113596.

Zhang P, et al. (2024) Acquired and intrinsic resistance to vemurafenib in BRAFV600E - driven melanoma brain metastases. *FEBS open bio*, 14(1), 96.

Ling H, et al. (2024) HDAC10 inhibition represses melanoma cell growth and BRAF inhibitor resistance via upregulating SPARC expression. *NAR cancer*, 6(2), zcae018.

Li Y, et al. (2024) IGSF8 is an innate immune checkpoint and cancer immunotherapy target.

Cell, 187(11), 2703.

Zhu L, et al. (2024) IFN- γ -responsiveness of lymphatic endothelial cells inhibits melanoma lymphatic dissemination via AMPK-mediated metabolic control. *Biochimica et biophysica acta. Molecular basis of disease*, 1870(7), 167314.

Nguyen TN, et al. (2024) Transcriptional and functional regulation of cell cycle and UV response by PPAR γ in human skin epidermal cells. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 38(23), e70212.

Wang H, et al. (2024) Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma. *Cell reports*, 43(12), 115015.

Martínez-Quintanilla J, et al. (2024) Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(18), 4082.

Waddell A, et al. (2024) p300 KAT Regulates SOX10 Stability and Function in Human Melanoma. *Cancer research communications*, 4(8), 1894.

Zhu X, et al. (2024) NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAMPT-deficient pan-cancers. *Cell chemical biology*, 31(6), 1203.

Hofman DA, et al. (2024) Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. *Molecular cell*, 84(2), 261.

Tao H, et al. (2024) PRMT1 Inhibition Activates the Interferon Pathway to Potentiate Antitumor Immunity and Enhance Checkpoint Blockade Efficacy in Melanoma. *Cancer research*, 84(3), 419.

Sandor LF, et al. (2024) De novo steroidogenesis in tumor cells drives bone metastasis and osteoclastogenesis. *Cell reports*, 43(3), 113936.

Kopparapu PR, et al. (2024) Identification and Characterization of a Small Molecule Bcl-2 Functional Converter. *Cancer research communications*, 4(3), 634.

Murali VS, et al. (2024) RhoA activation promotes glucose uptake to elevate proliferation in MAPK inhibitor resistant melanoma cells. *bioRxiv : the preprint server for biology*.

Wang Y, et al. (2024) Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors. *Cell reports. Medicine*, 5(1), 101374.

Martins C, et al. (2024) Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling. *Science advances*, 10(3), eadi2012.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell*

chemical biology, 31(7), 1247.

Becker AMD, et al. (2024) Inhibition of CSF-1R and IL-6R prevents conversion of cDC2s into immune incompetent tumor-induced DC3s boosting DC-driven therapy potential. *Cell reports. Medicine*, 5(2), 101386.